^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel has included bevacizumab as a therapeutic option for patients with non-clear RCC (2A).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel recommends bevacizumab plus everolimus (category 2A) for select patients with advanced RCC with non- clear cell histology.
    Secondary therapy:
    everolimus